期刊
NEUROPSYCHOPHARMACOLOGY
卷 37, 期 1, 页码 77-101出版社
SPRINGERNATURE
DOI: 10.1038/npp.2011.198
关键词
mood disorders; clinical pharmacology; clinical trials; neurotransmission; circadian; signal transduction
资金
- NIMH
- American Foundation for Suicide Prevention (AFSP)
- Corcept
- Ortho-McNeil-Janssen
- Otsuka
- Novartis
- NIAAA
- National Alliance for Schizophrenia and Depression (NARSAD)
- Mayo Foundation
- Pfizer
- AHRQ
- NARSAD
- Bristol-Myers Squibb
- Eli Lilly and Company
- Euthymics Bioscience
- Forest Pharmaceuticals
- Janssen Pharmaceutica
- Novartis Pharmaceuticals
- Otsuka Pharmaceuticals
- Pamlab
- Pfizer Inc.
- Repligen Corp.
- St Jude Medical
After a series of serendipitous discoveries of pharmacological treatments for mania and depression several decades ago, relatively little progress has been made for novel hypothesis-driven drug development in mood disorders. Multifactorial etiologies of, and lack of a full understanding of, the core neurobiology of these conditions clearly have contributed to these development challenges. There are, however, relatively novel targets that have raised opportunities for progress in the field, such as glutamate and cholinergic receptor modulators, circadian regulators, and enzyme inhibitors, for alternative treatment. This review will discuss these promising new treatments in mood disorders, the underlying mechanisms of action, and critical issues of their clinical application. For these new treatments to be successful in clinical practice, it is also important to design innovative clinical trials that identify the specific actions of new drugs, and, ideally, to develop biomarkers for monitoring individualized treatment response. It is predicted that future drug development will identify new agents targeting the molecular mechanisms involved in the pathophysiology of mood disorders. Neuropsychopharmacology Reviews (2012) 37, 77-101; doi: 10.1038/npp.2011.198; published online 7 September 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据